Longboard Pharmaceuticals Inc (LBPH) PT Raised to $42 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi Reiterates Buy Rating on Longboard Pharmaceuticals Inc (LBPH)
June 11, 2024 5:37 AM EDTCiti analyst David Hoang reiterated a Buy rating and $40.00 price target on Longboard Pharmaceuticals Inc (NASDAQ: LBPH).
The analyst comments "LBPH reported a first data cut from the PACIFIC OLE study that supports our thesis for bexicaserin to become a blockbuster product with... More
Longboard Pharmaceuticals Inc (LBPH) PT Raised to $36 at B.Riley
June 10, 2024 4:21 PM EDTB.Riley analyst Kalpit Patel raised the price target on Longboard Pharmaceuticals Inc (NASDAQ: LBPH) to $36.00 (from $30.00) while maintaining a Buy rating.
The analyst comments "On Monday (6/10), Longboard Pharma (LBPHBuy, $36 PT) delivered an update from the open-label extension portion of the PACIFIC... More
